NEW YORK (GenomeWeb) – Meridian Bioscience reported today that its fiscal third quarter revenues rose 5 percent year over year, driven largely by its newly-acquired Magellan Diagnostics business.

For the three months ended June 30, Meridian posted net revenues of $50.7 million compared to $48.2 million in the year ago quarter, and missing analysts' consensus estimate of $52.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.